Company intelligence / Profile preview

Aevum

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Research has shown that irisin prevented the accumulation of alpha synuclein clumps and associated brain cell death in laboratory models. In mice with Parkinson's-like symptoms, irisin treatment resulted in no muscle movement deficits compared to placebo groups, and lowered levels of Parkinson's disease-related alpha synuclein between 50% and 80%.

Therapeutic areas: Neurology
Modalities: Peptide therapeutics
Industry: Biotech

Beyond the preview

Go deeper on Aevum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aevum.

Explore the full profile